Source: http://www.allegroeye.com/
SAN JUAN CAPISTRANO, CA — October 3, 2016 — Allegro Ophthalmics, LLC, a biotechnology company focused on the development of therapies to treat vitreoretinal diseases, today announced completion of enrollment in its PACIFIC Phase 2b clinical trial that is evaluating the safety and efficacy of Luminate® (ALG-1001) in inducing posterior vitreous detachment (PVD) in patients with non-proliferative diabetic retinopathy (DR).
“We are very pleased to have completed patient enrollment in the PACIFIC trial,” said Vicken Karageozian, M.D., President and Chief Medical Officer, Allegro Ophthalmics. “There are currently no practical treatment options available for PVD induction in non-proliferative DR, resulting in a significant need for novel, non-surgical treatments that optimize long-term clinical outcomes. We are optimistic that Luminate will continue to show efficacy and provide meaningful therapeutic benefit to patients with diabetic retinopathy and other vitreoretinal diseases.”
PACIFIC is the third Phase 2 study of Luminate to complete enrollment. Top-line results from PACIFIC are anticipated to be available within the first half of 2017, and those from the DEL MAR Phase 2b trials evaluating Luminate in patients with diabetic macular edema (DME) are expected Q4 2016.
Read more: http://www.allegroeye.com/press-release/allegro-ophthalmics-announces-last-patient-enrolled-in-pacific-phase-2b-clinical-trial-of-luminate-for-non-proliferative-diabetic-retinopathy/